HC Wainwright Reaffirms “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

HC Wainwright reissued their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $50.00 price target on the stock.

GMAB has been the topic of several other reports. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Redburn Atlantic started coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Trading Up 0.0 %

Shares of GMAB stock opened at $22.19 on Wednesday. The company has a market capitalization of $14.68 billion, a price-to-earnings ratio of 21.54, a P/E/G ratio of 0.63 and a beta of 0.97. Genmab A/S has a 1-year low of $19.85 and a 1-year high of $32.56. The stock’s fifty day simple moving average is $21.33 and its 200-day simple moving average is $24.26.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. During the same period last year, the company earned $0.47 earnings per share. On average, sell-side analysts predict that Genmab A/S will post 1.28 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GMAB. GAMMA Investing LLC lifted its position in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after acquiring an additional 3,880 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after acquiring an additional 1,413 shares during the last quarter. Headlands Technologies LLC increased its position in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after acquiring an additional 4,853 shares during the period. Finally, Benjamin F. Edwards & Company Inc. raised its stake in Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.